469 related articles for article (PubMed ID: 29105160)
1. Strength in Amalgamation: Newer Combination Agents for HIV and Implications for Practice.
McCoy C; Badowski M; Sherman E; Crutchley R; Smith E; Chastain DB;
Pharmacotherapy; 2018 Jan; 38(1):86-107. PubMed ID: 29105160
[TBL] [Abstract][Full Text] [Related]
2. Impact of switching to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG on cardiovascular risk and lipid profile in people living with HIV: a retrospective cohort study.
Giacomelli A; Conti F; Pezzati L; Oreni L; Ridolfo AL; Morena V; Bonazzetti C; Pagani G; Formenti T; Galli M; Rusconi S
BMC Infect Dis; 2021 Jun; 21(1):595. PubMed ID: 34157984
[TBL] [Abstract][Full Text] [Related]
3. Combinational therapies for HIV: a focus on EVG/COBI/FTC/TDF.
Schrijvers R; Debyser Z
Expert Opin Pharmacother; 2012 Sep; 13(13):1969-83. PubMed ID: 22849516
[TBL] [Abstract][Full Text] [Related]
4. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial.
DeJesus E; Rockstroh JK; Henry K; Molina JM; Gathe J; Ramanathan S; Wei X; Yale K; Szwarcberg J; White K; Cheng AK; Kearney BP;
Lancet; 2012 Jun; 379(9835):2429-2438. PubMed ID: 22748590
[TBL] [Abstract][Full Text] [Related]
5. Co-administration of elvitegravir/cobicistat/tenofovir disoproxil fumarate/emtricitabine and atazanavir in treatment-experienced HIV patients.
Biagi M; Badowski ME; Chiampas T; Young J; Patel M; Vaughn P
Int J STD AIDS; 2017 Jul; 28(8):766-772. PubMed ID: 27587601
[TBL] [Abstract][Full Text] [Related]
6. Switching regimens in virologically suppressed HIV-1-infected patients: evidence base and rationale for integrase strand transfer inhibitor (INSTI)-containing regimens.
Raffi F; Esser S; Nunnari G; Pérez-Valero I; Waters L
HIV Med; 2016 Oct; 17 Suppl 5():3-16. PubMed ID: 27714978
[TBL] [Abstract][Full Text] [Related]
7. Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIV.
Imaz A; Podzamczer D
Expert Rev Anti Infect Ther; 2017 Mar; 15(3):195-209. PubMed ID: 28117606
[TBL] [Abstract][Full Text] [Related]
8. Comparing Real-World Healthcare Costs Associated with Single-Tablet Regimens for HIV-1: The 2-Drug Regimen Dolutegravir/Lamivudine vs. Standard 3- or 4-Drug Regimens.
Priest J; Germain G; Laliberté F; Duh MS; Mahendran M; Fakih I; Oglesby A
Infect Dis Ther; 2023 Aug; 12(8):2117-2133. PubMed ID: 37552426
[TBL] [Abstract][Full Text] [Related]
9. Real-world adherence and persistence for newly-prescribed HIV treatment: single versus multiple tablet regimen comparison among US medicaid beneficiaries.
Cohen J; Beaubrun A; Bashyal R; Huang A; Li J; Baser O
AIDS Res Ther; 2020 Apr; 17(1):12. PubMed ID: 32238169
[TBL] [Abstract][Full Text] [Related]
10. Darunavir-cobicistat-emtricitabine-tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era.
Squillace N; Bozzi G; Colella E; Gori A; Bandera A
Drug Des Devel Ther; 2018; 12():3635-3643. PubMed ID: 30464395
[TBL] [Abstract][Full Text] [Related]
11. A Review of the Efficacy and Safety of Genvoya® (Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide) in the Management of HIV-1 Infection.
Angione SA; Cherian SM; Özdener AE
J Pharm Pract; 2018 Apr; 31(2):216-221. PubMed ID: 28558493
[TBL] [Abstract][Full Text] [Related]
12. Fixed dose darunavir boosted with cobicistat combined with emtricitabine and tenofovir alafenamide fumarate.
Cevik M; Orkin C
Curr Opin HIV AIDS; 2018 Jul; 13(4):315-319. PubMed ID: 29528852
[TBL] [Abstract][Full Text] [Related]
13. Brief Report: Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in Virologically Suppressed Women.
Hodder S; Squires K; Kityo C; Hagins D; Avihingsanon A; Kido A; Jiang S; Kulkarni R; Cheng A; Cao H
J Acquir Immune Defic Syndr; 2018 Jun; 78(2):209-213. PubMed ID: 29481486
[TBL] [Abstract][Full Text] [Related]
14. A four-drug combination oral tablet of darunavir, cobicistat, emtricitabine, and tenofovir alafenamide for the treatment of HIV-1 infection in adults.
Muccini C; Castagna A
Expert Rev Anti Infect Ther; 2023; 21(11):1167-1176. PubMed ID: 37800640
[TBL] [Abstract][Full Text] [Related]
15. An indirect comparison of 144-week efficacy, safety, and tolerability of dolutegravir plus lamivudine and second-generation integrase inhibitor-based, 3-drug, single-tablet regimens in therapy-naive people with HIV-1.
Evitt LA; Nanji S; Grove RA; Okoli C; van Wyk J; Snedecor SJ
AIDS Res Ther; 2023 Mar; 20(1):17. PubMed ID: 36949442
[TBL] [Abstract][Full Text] [Related]
16. Durability of first-line antiretroviral regimens in the era of integrase inhibitors: a cohort of HIV-positive individuals in Spain, 2014-2015.
Jarrin I; Suarez-Garcia I; Moreno C; Tasias M; Del Romero J; Palacios R; Peraire J; Gorgolas M; Moreno S;
Antivir Ther; 2019; 24(3):167-175. PubMed ID: 30747107
[TBL] [Abstract][Full Text] [Related]
17. Real-World Assessment of Renal and Bone Safety among Patients with HIV Infection Exposed to Tenofovir Disoproxil Fumarate-Containing Single-Tablet Regimens.
Nkhoma ET; Rosenblatt L; Myers J; Villasis-Keever A; Coumbis J
PLoS One; 2016; 11(12):e0166982. PubMed ID: 27941989
[TBL] [Abstract][Full Text] [Related]
18. An indirect comparison of efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir and dolutegravir + abacavir/lamivudine.
Rogatto F; Bouee S; Jeanbat V; Piontkowsky D; Aragao F; Bosse M
J Int AIDS Soc; 2014; 17(4 Suppl 3):19779. PubMed ID: 25397523
[TBL] [Abstract][Full Text] [Related]
19. Choice of the initial antiretroviral treatment for HIV-positive individuals in the era of integrase inhibitors.
Alejos B; Suárez-García I; Bisbal O; Iribarren JA; Asensi V; Górgolas M; Muga R; Moreno S; Jarrín I;
PLoS One; 2019; 14(8):e0221598. PubMed ID: 31449566
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]